Truscreen Group Ltd
Company Profile
Business description
Truscreen Group Ltd is a medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The company develops, manufactures, and sells cancer detection devices and systems. Its products include The TrueScreen device and HPV Test kits. It operates in one operating segment. It owns the rights to the TruScreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real time of precancerous and cancerous tissue on the cervix. Geographically, it operates in Mexico, China, Central Asia, Vietnam, Zimbabwe, Indonesia, India, and MENA (Middle East/North Africa), with the majority of revenue deriving from China.
Contact
C/- HLB Mann Judd Limited
57 Symonds Street
Level 6, Equitable House
Grafton
AucklandNTL1010
NZLT: +64 93032243
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
stocks
This onetime AI market darling is now surprisingly undervalued
stocks
Undervalued ASX miner hits production homerun
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |